Clear Trail Advisors LLC Takes Position in Amgen Inc. $AMGN

Clear Trail Advisors LLC purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 8,059 shares of the medical research company’s stock, valued at approximately $2,638,000.

Several other large investors also recently bought and sold shares of the business. SG Americas Securities LLC grew its stake in Amgen by 40.2% during the 4th quarter. SG Americas Securities LLC now owns 397,219 shares of the medical research company’s stock valued at $130,014,000 after acquiring an additional 113,909 shares in the last quarter. Breakwater Capital Group lifted its stake in Amgen by 5.3% in the 4th quarter. Breakwater Capital Group now owns 2,010 shares of the medical research company’s stock worth $658,000 after purchasing an additional 101 shares in the last quarter. Post Resch Tallon Group Inc. boosted its holdings in shares of Amgen by 4.5% during the 4th quarter. Post Resch Tallon Group Inc. now owns 1,036 shares of the medical research company’s stock worth $339,000 after purchasing an additional 45 shares during the last quarter. Affinity Capital Advisors LLC boosted its holdings in shares of Amgen by 21.0% during the 4th quarter. Affinity Capital Advisors LLC now owns 1,033 shares of the medical research company’s stock worth $338,000 after purchasing an additional 179 shares during the last quarter. Finally, TABR Capital Management LLC purchased a new stake in shares of Amgen in the fourth quarter valued at approximately $267,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 0.6%

Shares of Amgen stock opened at $349.77 on Tuesday. The stock has a 50 day moving average of $360.77 and a 200 day moving average of $328.60. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The firm has a market capitalization of $188.55 billion, a price-to-earnings ratio of 24.58, a PEG ratio of 3.45 and a beta of 0.45. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the previous year, the business earned $5.31 earnings per share. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is 70.84%.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. HSBC reaffirmed a “buy” rating and issued a $425.00 price target on shares of Amgen in a report on Wednesday, December 10th. Piper Sandler upped their target price on Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. BMO Capital Markets raised their target price on Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. Finally, Wells Fargo & Company boosted their price target on shares of Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a research report on Thursday, March 19th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $354.60.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.